hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06362577, orgStudyIdInfo id: TSC202202, briefTitle: Clinical Study of HIFU for Localized Prostate Cancer, acronym: HIFU, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-15, primaryCompletionDateStruct date: 2025-11-30, completionDateStruct date: 2026-12-31, studyFirstPostDateStruct date: 2024-04-12, lastUpdatePostDateStruct date: 2024-04-12, sponsorCollaboratorsModule leadSponsor name: RenJi Hospital, class: OTHER, descriptionModule briefSummary: In this study, the safety and effectiveness data of Sonablate system, a transrectal high-intensity focused ultrasound therapeutic instrument, in the treatment of localized prostate cancer were collected, and the treatment conditions of patients with other methods (such as radical prostatectomy) were compared and analyzed. Observe the differences in treatment effect, survival rate, postoperative PSA, recurrence and complications.To analyze and compare the clinical outcome, postoperative complications and tumor control of HIFU and robot-assisted laparoscopic radical prostatectomy for localized prostate cancer, and to explore the effectiveness and safety of HIFU in the treatment of localized prostate cancer, so as to provide an alternative treatment for localized prostate cancer., conditionsModule conditions: Localized Prostate Cancer, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: RETROSPECTIVE, enrollmentInfo count: 100, type: ESTIMATED, armsInterventionsModule interventions name: EQ-5D-5L IPSS IIEF-5 EPIC-26 ECOG, outcomesModule primaryOutcomes measure: Incidence of postoperative complications, secondaryOutcomes measure: The time to reach the lowest point of PSA, secondaryOutcomes measure: Assessment of quality of life and sexual function spontaneously reported at 2, 6, and 12 months after surgery, secondaryOutcomes measure: The negative rate of tumor exclusion was evaluated by imaging (mainly mp-MRI) at 2 and 12 months after surgery, secondaryOutcomes measure: The incidence of biochemical recurrence that requires remedial or systemic treatment 12 months after surgery, secondaryOutcomes measure: Postoperative overall survival rate, eligibilityModule sex: MALE, minimumAge: 40 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06362564, orgStudyIdInfo id: CIPL-LBE-0101, briefTitle: [Trial of device that is not approved or cleared by the U.S. FDA], statusModule overallStatus: WITHHELD, studyFirstPostDateStruct date: 2024-04-12, lastUpdatePostDateStruct date: 2024-04-12, sponsorCollaboratorsModule leadSponsor name: [Redacted], hasResults: False
protocolSection identificationModule nctId: NCT06362551, orgStudyIdInfo id: INC-GS-2024-002, briefTitle: Oocyte Donor Application Discrepancies, statusModule overallStatus: ACTIVE_NOT_RECRUITING, startDateStruct date: 2024-03-25, primaryCompletionDateStruct date: 2024-05, completionDateStruct date: 2025-05, studyFirstPostDateStruct date: 2024-04-12, lastUpdatePostDateStruct date: 2024-04-12, sponsorCollaboratorsModule leadSponsor name: Inception Fertility, LLC, class: INDUSTRY, collaborators name: GeneScreen Counseling, LLC, descriptionModule briefSummary: Retrospective observational study comparing information received on Inception Central Donor Recruitment's standardized online egg donor application compared to information reported during a genetic risk assessment consultation with a certified genetic counselor with contracted third party genetic counseling service, GeneScreen. All donor applicants completing a full application with Inception's Central Donor Recruitment and a GRA consultation with GeneScreen will be included., conditionsModule conditions: Infertility, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_ONLY, timePerspective: RETROSPECTIVE, enrollmentInfo count: 1000, type: ESTIMATED, outcomesModule primaryOutcomes measure: Rate of additional information, primaryOutcomes measure: Rate of applicant decline, eligibilityModule sex: FEMALE, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Inception Fertility LLC, city: Houston, state: Texas, zip: 77081, country: United States, geoPoint lat: 29.76328, lon: -95.36327, hasResults: False
protocolSection identificationModule nctId: NCT06362538, orgStudyIdInfo id: MCH-ProCardioPrev, briefTitle: The Cardiovascular Prevention Program, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-15, primaryCompletionDateStruct date: 2027-04-15, completionDateStruct date: 2027-04-15, studyFirstPostDateStruct date: 2024-04-12, lastUpdatePostDateStruct date: 2024-04-16, sponsorCollaboratorsModule leadSponsor name: Maria Cecilia Hospital, class: OTHER, descriptionModule briefSummary: Cardiovascular diseases represent one of the main public health problems being the leading cause of morbidity, disability and mortality. In recent decades, the global prevalence and cardiovascular disease mortality has increased, with 23.6 million annual deaths expected by 2030. In Europe, mortality per year is equal to 2.2 million women and 1.9 million men, representing 47% and 37% of all deaths respectively. In Italy, the situation in terms of deaths due to cardiovascular diseases it is in line with the world ranking and European, being responsible for 44% of all deaths. The only interventional or pharmacological approach is neither effective nor sustainable. The most deaths from cardiovascular diseases are due to atherothrombotic events, which are attributable to a series of risk factors, most of which are modifiable. Turns out itself as a targeted action on these factors with the aim of safeguarding the state of health cardiovascular, may represent the best applicable strategy. It is therefore necessary structure and activate prevention programs aimed at the general population and groups of subjects at higher risk., conditionsModule conditions: Cardiovascular Prevention, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SEQUENTIAL, primaryPurpose: PREVENTION, maskingInfo masking: NONE, enrollmentInfo count: 150, type: ESTIMATED, armsInterventionsModule interventions name: International Physical Activity Questionnaire, interventions name: Six minute walking test, interventions name: SF-36, Euro-Qol 5D-5L, Perceived stress scale-10, Pittsburgh Sleep Quality Index, Depression Anxiety Stress scale- 21., interventions name: MEDAS, interventions name: Intima-media thickness (IMT), interventions name: Blood sampling, interventions name: Stool Sample Culture Test, outcomesModule primaryOutcomes measure: measure of body mass index, primaryOutcomes measure: Adherence to the Mediterranean diet, primaryOutcomes measure: blood test to check cholesterol levels, primaryOutcomes measure: blood pressure measurement, primaryOutcomes measure: blood glucose test, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 30 Years, stdAges: ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06362525, orgStudyIdInfo id: 2022-389, briefTitle: Incidence of Episodes of (Dis)Connected Consciousness Among Emergency Patients Admitted in the Resuscitation Room, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-10-09, primaryCompletionDateStruct date: 2025-09-30, completionDateStruct date: 2027-09-30, studyFirstPostDateStruct date: 2024-04-12, lastUpdatePostDateStruct date: 2024-04-12, sponsorCollaboratorsModule leadSponsor name: University of Liege, class: OTHER, collaborators name: Centre Hospitalier Universitaire de Liege, descriptionModule briefSummary: This observational study aims to describe the incidence of episodes of disconnected consciousness (including near-death experience (NDE)) and episodes of connected consciousness in patients admitted to the resuscitation room, who survived a critical condition and who meet at least one of these criteria during their stay in the resuscitation room: (1) deep sedation, (2) intubation, (3) cardiopulmonary resuscitation, or (4) (non-drug-induced) Glasgow Coma Scale score = 3. We also investigate the potential (neuro)physiological markers and biomarkers. In order to help determine the potential risk factors of such episodes, cognitive factors such as dissociative propensity are also investigated. Unexpected visual and auditory stimuli will be displayed. In addition, we assess the evolution of memory, as well as short- and long-term consequences on quality of life, anxiety, and attitudes towards care.Memory of patients who did not meet the above-mentioned criteria are also investigated. A group of 15 healthy participants will be invited to test the stimuli display.Finally, (neuro)physiological parameters of a subsample of dying patients are also investigated., conditionsModule conditions: Critical Illness, conditions: Near-Death Experience, conditions: Consciousness, Loss of, conditions: Quality of Life, conditions: Emergencies, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 100, type: ESTIMATED, outcomesModule primaryOutcomes measure: Detection of potential episodes of disconnected consciousness, primaryOutcomes measure: Detection of potential episodes of connected consciousness, secondaryOutcomes measure: Risk factors, secondaryOutcomes measure: Quality of life assessment, secondaryOutcomes measure: Memory content and evolution assessment, secondaryOutcomes measure: Detection of post-traumatic stress disorder (PTSD), eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: CHU of Liège, status: RECRUITING, city: Liège, zip: 4000, country: Belgium, geoPoint lat: 50.63373, lon: 5.56749, hasResults: False
protocolSection identificationModule nctId: NCT06362512, orgStudyIdInfo id: Marco_PANG_2024, briefTitle: Cognitive-motor Exercise for Stroke Patients in Function, Cognition and Related Brain Changes., acronym: COGMOTION, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-04, primaryCompletionDateStruct date: 2026-04, completionDateStruct date: 2026-04, studyFirstPostDateStruct date: 2024-04-12, lastUpdatePostDateStruct date: 2024-04-16, sponsorCollaboratorsModule leadSponsor name: The Hong Kong Polytechnic University, class: OTHER, descriptionModule briefSummary: The purpose of this study is to evaluate a cognitive-motor exercise on dual-task interference during dual-task ankle movement and the corresponding alterations of brain activity., conditionsModule conditions: Stroke, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: After stratification according to gender and walking speed, the participants will be randomly allocated to one of three groups: (1) dual-task training, (2) single-task training, and (3) control intervention, using a 1:1:1 allocation ratio., primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, maskingDescription: This will be a single-blinded randomized controlled trial . The assessor will be blinded during assessments. The participants and investigators (trainers) are not possible to be blinded as it is an exercise intervention., whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 84, type: ESTIMATED, armsInterventionsModule interventions name: Dual-task training, interventions name: Single-task training, interventions name: Upper limb strengthening exercise, outcomesModule primaryOutcomes measure: Dual-task step frequency, primaryOutcomes measure: Dual-task cognitive performance accuracy, secondaryOutcomes measure: Blood oxygenation level changes of the brain, otherOutcomes measure: Single-task walking speed, otherOutcomes measure: Dual-task walking performance, otherOutcomes measure: Mini Balance Evaluation Systems Test, otherOutcomes measure: Activities-specific Balance Confidence Scale, otherOutcomes measure: Trail Making Test, otherOutcomes measure: Digit Span Test, otherOutcomes measure: Montreal Cognitive Assessment, otherOutcomes measure: Fall incidence, otherOutcomes measure: Dual-task ankle movement degree, otherOutcomes measure: Dual-task cognitive performance time, eligibilityModule sex: ALL, minimumAge: 50 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: The Hong Kong Polytechnic University, status: RECRUITING, city: Hong Kong, zip: 000000, country: China, contacts name: Marco Yiu Chung Pang, PhD, role: CONTACT, geoPoint lat: 22.39407, lon: 114.13737, hasResults: False
protocolSection identificationModule nctId: NCT06362499, orgStudyIdInfo id: 01, briefTitle: Effects of Unsupervised Inspiratory Muscle Training on Ventilation Variability in Post-covid-19 Patients., statusModule overallStatus: RECRUITING, startDateStruct date: 2024-04-01, primaryCompletionDateStruct date: 2024-07-31, completionDateStruct date: 2024-07-31, studyFirstPostDateStruct date: 2024-04-12, lastUpdatePostDateStruct date: 2024-04-17, sponsorCollaboratorsModule leadSponsor name: Universidade Federal do Rio Grande do Norte, class: OTHER, descriptionModule briefSummary: Dysfunctional breathing and persistent hypocapnia can be associated with many of the symptoms experienced by patients such as dyspnea, fatigue, chest pain and palpitations. The identification of dysfunctional breathing and hypocapnia in these patients is important as it may represent a target for treatment.In many of these patients, tachypnea at low levels of exertion suggests increased respiratory muscle activity, which can lead to the sensation of dyspnea. Sympathetic hyperactivity leads to excessive and irregular ventilation during exercise. In this way, inspiratory muscle training can improve symptoms (dysfunctional breathing), possibly by attenuating the metaboreflex (vagal modulation-attenuation of the sympathetic response) of the inspiratory muscle in post-covid-19 subjects, reducing ventilatory variability., conditionsModule conditions: COVID-19, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: TRIPLE, whoMasked: PARTICIPANT, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 24, type: ESTIMATED, armsInterventionsModule interventions name: Experimental Group, outcomesModule primaryOutcomes measure: Ventilation variability and ventilation efficiency, secondaryOutcomes measure: Respiratory muscle strength, secondaryOutcomes measure: Pulmonary function, secondaryOutcomes measure: Quality of life - Medical Outcomes Study 36-Item Short Health Form Survey (SF-36), secondaryOutcomes measure: Peripheral muscle strength, secondaryOutcomes measure: Functional capacity, secondaryOutcomes measure: Adverse effects and adherence, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 55 Years, stdAges: ADULT, contactsLocationsModule locations facility: Federal University of Rio Grande do Norte, status: RECRUITING, city: Natal, state: Rio Grande Do Norte, zip: 59082-100, country: Brazil, contacts name: Gabriely Azevêdo, role: CONTACT, phone: 84999390004, email: gabrielyazevedo.ga@gmail.com, contacts name: Patrícia Nogueira, role: CONTACT, geoPoint lat: -5.795, lon: -35.20944, locations facility: Patrícia Nogueira, status: RECRUITING, city: Natal, state: Rio Grande Do Norte, country: Brazil, contacts name: Patrícia Nogueira, role: CONTACT, contacts name: Gabriely Azevêdo, role: CONTACT, phone: 5584999390004, email: gabrielyazevedo.ga@gmail.com, geoPoint lat: -5.795, lon: -35.20944, hasResults: False
protocolSection identificationModule nctId: NCT06362460, orgStudyIdInfo id: RAY1216-23-03, briefTitle: Mass Balance Study of [14C]RAY1216 in Healthy Adult Male Subjects in China, statusModule overallStatus: COMPLETED, startDateStruct date: 2023-09-18, primaryCompletionDateStruct date: 2023-11-01, completionDateStruct date: 2023-11-15, studyFirstPostDateStruct date: 2024-04-12, lastUpdatePostDateStruct date: 2024-04-16, sponsorCollaboratorsModule leadSponsor name: Guangdong Raynovent Biotech Co., Ltd, class: INDUSTRY, descriptionModule briefSummary: This study is a single-center, open-label, and single-dose clinical study to evaluate the mass balance, biotransformation and pharmacokinetics of \[14C\]RAY1216 in healthy Chinese male participants, revealing the overall pharmacokinetic characteristics of RAY1216., conditionsModule conditions: Pharmacokinetics, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: BASIC_SCIENCE, maskingInfo masking: NONE, enrollmentInfo count: 6, type: ACTUAL, armsInterventionsModule interventions name: [14C] RAY1216, outcomesModule primaryOutcomes measure: Total radioactivity in plasma PK, primaryOutcomes measure: Total radioactivity in plasma PK, primaryOutcomes measure: Total radioactivity in plasma PK, primaryOutcomes measure: Total radioactivity in plasma PK, primaryOutcomes measure: Mass balance recovery of total radioactivity in all (urine, faeces) amount excreted (Ae) expressed as a percentage of the administered dose (%Ae), secondaryOutcomes measure: Number of Participants with Treatment-Related Adverse Events as Assessed by CTCAE v5.0, eligibilityModule sex: MALE, minimumAge: 18 Years, maximumAge: 45 Years, stdAges: ADULT, contactsLocationsModule locations facility: The First Affiliated Hospital of Bengbu Medical College, city: Bengbu, country: China, geoPoint lat: 32.94083, lon: 117.36083, hasResults: False
protocolSection identificationModule nctId: NCT06362447, orgStudyIdInfo id: RC31/22/0320, briefTitle: Efficacy of Injectable Gentamicin in Hereditary Ichthyosis, acronym: GENTIC, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-23, primaryCompletionDateStruct date: 2026-04-01, completionDateStruct date: 2027-04-01, studyFirstPostDateStruct date: 2024-04-12, lastUpdatePostDateStruct date: 2024-04-12, sponsorCollaboratorsModule leadSponsor name: University Hospital, Toulouse, class: OTHER, descriptionModule briefSummary: This study will evaluate the efficacy and safety of intravenous gentamicin in congenital ichthyosis due to a non-sens mutation. The primary objective is the severity of scales and erythema at the third month, compared to baseline. Secondary objectives will include: the importance of itching, trans epidermal water loss, cutaneous expression of the targeted protein, the security of the drug and patients' satisfaction., conditionsModule conditions: Ichthyosis, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 26, type: ESTIMATED, armsInterventionsModule interventions name: Gentamicin Injectable Solution, outcomesModule primaryOutcomes measure: Gentamicin efficacity, secondaryOutcomes measure: Gentamicin efficacity, secondaryOutcomes measure: Gentamicin efficacity on quality of life, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Hôpital Saint-Louis APHP, city: Paris, zip: 75010, country: France, contacts name: BOURRAT Emmanuelle, MD, role: CONTACT, phone: 01 42 49 90 90, phoneExt: 33, email: emmanuelle.bourrat@aphp.fr, geoPoint lat: 48.85341, lon: 2.3488, locations facility: CHU de Toulouse, city: Toulouse, zip: 31059, country: France, contacts name: SEVERINO-FREIRE Maella, MD, role: CONTACT, phone: 05 67 77 81 41, phoneExt: 33, email: severino-freire.m@chu-toulouse.fr, contacts name: TEXIER Hélène, role: CONTACT, phone: 05 67 77 81 80, phoneExt: 33, email: texier.h@chu-toulouse.fr, contacts name: MAZEREEUW-HAUTIER Juliette, MD, PhD, role: SUB_INVESTIGATOR, geoPoint lat: 43.60426, lon: 1.44367, hasResults: False
protocolSection identificationModule nctId: NCT06362421, orgStudyIdInfo id: ONC-HN-2402, briefTitle: Saliva Testing for High-Risk Human Papillomavirus Infection Oral Cavity and Pharynx Cancer, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-06, primaryCompletionDateStruct date: 2026-06, completionDateStruct date: 2026-07, studyFirstPostDateStruct date: 2024-04-12, lastUpdatePostDateStruct date: 2024-04-12, sponsorCollaboratorsModule leadSponsor name: Wake Forest University Health Sciences, class: OTHER, collaborators name: InnoTech Precision Medicine, descriptionModule briefSummary: The purpose of this research study is to determine if saliva and oral swab samples can be used to detect human papillomavirus in patients with cancer. In this study, the methods required to detect human papillomavirus will be developed and tested in samples collected from patients with oropharyngeal squamous cell carcinoma and compared to samples collected from participants without cancer., conditionsModule conditions: Oropharyngeal Squamous Cell Carcinoma, conditions: Human Papillomavirus Infection, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 80, type: ESTIMATED, armsInterventionsModule interventions name: Pre-Radiation Dental Evaluation/Sample Collection, interventions name: Pre-Study Visit, interventions name: Oral Medicine Consultation Visit/Sample Collection, outcomesModule primaryOutcomes measure: Number of Participants with Sensitivity for Detection of HPV 16, 18 and gene ACTB, primaryOutcomes measure: Number of Participants with Specificity Detection of HPV 16, 18 and gene ACTB, primaryOutcomes measure: Overall Accuracy - All Participants, eligibilityModule sex: ALL, minimumAge: 39 Years, maximumAge: 59 Years, stdAges: ADULT, contactsLocationsModule locations facility: Hayworth Cancer Center, city: High Point, state: North Carolina, zip: 27262, country: United States, contacts name: Study Coordinator, role: CONTACT, phone: 336-713-1790, email: cbynum@wakehealth.edu, geoPoint lat: 35.95569, lon: -80.00532, locations facility: Atrium Health Wake Forest Baptist Comprehensive Cancer Center, city: Winston-Salem, state: North Carolina, zip: 27157, country: United States, contacts name: Study Coordinator, role: CONTACT, phone: 336-713-1790, email: cbynum@wakehealth.edu, contacts name: Muhammad A Shazib, DMD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 36.09986, lon: -80.24422, hasResults: False